Navigation Links
Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients
Date:3/23/2009

Randomized, Controlled, Multicenter Trial Will Test Ability of Adecatumumab to Prolong Disease Free Survival in High Risk Patients with Liver Metastases

BETHESDA, Md., March 23 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the commencement of a randomized, controlled phase 2 trial of its human anti-EpCAM IgG1 antibody adecatumumab (MT201) for the treatment of patients with colorectal cancer (CRC) after complete resection of liver metastases. The trial has three arms comparing single agent adecatumumab to combination chemotherapy (FOLFOX: 5-FU/Leucovorin plus Oxaliplatin), and to FOLFOX followed by adecatumumab. The primary endpoint will be the disease-free survival rate at one year.

"The relapse of colorectal cancer patients with liver metastases still represents an area with very high medical need" said the trial's principle investigator, Professor Peter Neuhaus, from the Charite University Hospital in Berlin, Germany. "Recent intensification of chemotherapeutic regimens has shown only modest benefit and there is significant room for improvement in these patients. EpCAM is a cancer target which is highly expressed in colorectal cancer, and targeted therapies such as adecatumumab could become a major breakthrough in this setting if proven successful."

Apart from being the most highly and frequently expressed target antigen on colorectal cancer cells, EpCAM has recently been shown to drive tumor growth and to be expressed on colorectal cancer stem cells (1). The ability of adecatumumab to potentially control and eliminate newly developing metastases has been suggested in a recently reported Phase 2 trial of adecatumumab as monotherapy in metastatic
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Key Events for 2009
2. Micromet Expands Committed Equity Financing Facility to $75 Million
3. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
4. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
5. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
6. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
7. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
8. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
9. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
10. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
11. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
(Date:10/20/2014)... MOUNTAIN VIEW, Calif. , Oct. 20, 2014 /PRNewswire/ ... field of interventional pulmonology, today announced completion of enrollment ... schedule.  The RENEW Clinical Study is the FDA-approved IDE ... treatment for severe emphysema. It was anticipated ... US in February 2013, would take until the end ...
(Date:10/20/2014)... 2014 Valeritas, Inc., a leader in simple, ... Type 2 diabetes, announced today that it has received ... award was presented October 16 th at Cardinal,s ... . The Cardinal Health Supply ... of metrics specifically targeted at the importance of developing ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3
... Aug. 1, 2011 Biodel Inc. (Nasdaq: BIOD ... results on August 4, 2011.  Following the release of the ... call to discuss the results and provide an update on ... fiscal year 2011 results will be distributed4:15 pm EDT: , ...
... 2011 Reportlinker.com announces that a new ... catalogue: Insulin- Global ... This package contains 63 insulin market analyses ... Czech Republic,Denmark, Estonia, Finland, France, Germany, Greece, ...
Cached Medicine Technology:Insulin- Global 2
(Date:10/22/2014)... October 22, 2014 The ... which is dedicated to distribute health information technology ... delivery worldwide announced the development of six key ... expect when receiving healthcare. These are an expansion ... care: “providing care that is respectful of and ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most distinguished ... announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best ... world. , “iPower is one of the most reliable ... kinds of useful products for new and old clients. ... service and a number of features which will appeal ...
(Date:10/22/2014)... October 22, 2014 Lintelus, Inc., an ... Vice President of Sales, will be speaking on the ... Technology Expo on October 28, at the Holiday Inn ... a booth as well as a Tech Demo at ... can create a more engaging event experience. , The ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... fertilization (IVF) are only about half as likely as white ... new research indicates, and the racial disparity persists even when ... percent of white patients became pregnant after IVF, compared to ... 4,000 IVF cycles over two years to tease out the ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... country's greenest and cleanest city was not enough, Chandigarh is all ... become the first smoke-free city in the country. ... free by July 1. ,The joint capital of Punjab ... and buildings to ensure that smoking is restricted and the general ...
... a million less AIDS patients than has been widely believed, ... were reported here. ,The survey that was ... out under international supervision shows that India probably no longer ... the New York Times said Friday. ,An official ...
... epilepsy in developing countries are being denied an effective ... according to an editorial in this weeks BMJ. ... in developing countries to ensure that effective treatment is ... people with epilepsy who live in developing countries, around ...
... (hESC), those very young cells that are a biological blank ... to the workings of a wide variety of organs and ... slow to be realized because of the ongoing ethical debate ... its a politically charged issue in the U.S. because it ...
... of tumors and the response of tumors to radiation ... in turn limits oxygen delivery to the tumor, causing ... shown to trigger tumor resistance to radiation via the ... known as HIF-1regulated cytokines. In a study appearing online ...
... community hospita,l in Detroit with 285 beds, specializing in general ... failure, diabetes and obstetrics. ,Detroit is the largest ... a prosperous region. ,But Riverview is all ... week said it was losing too much money and already ...
Cached Medicine News:Health News:Chandigarh to Become India's First Smoke-free City 2Health News:India Has a Million Less AIDS Cases Than Believed: Study 2Health News:Dartmouth Professor Makes Case for Ethically Universal Stem Cell Lines 2Health News:Hospitals in Older Cities Close Down, Blacks Worst Affected 2Health News:Hospitals in Older Cities Close Down, Blacks Worst Affected 3
... As the leader in liquid handling, ... Finnpipette Novus, a pipette that combines simplicity, ... ergonomic design. Built on the results of ... the new Finnpipette Novus gives you the ...
... The StaRRsed-III is a system ... human blood samples. This rate may ... patients therapy. The sedimentation rate is ... hence is typically used in high-volume ...
... complete range of automatic systems for performing ... mL of blood. With the introduction of ... clinical diagnostic market a truly revolutionary testing ... limitation associated with the traditional ESR techique.,By ...
... The NEW VACUETTE erythrocyte sedimentation ... can help. The new generation unites ... analysers with whole range of additional ... of the erythrocyte sedimentation rate. Cost ...
Medicine Products: